KNSA - キニクサ・ファ―マシュ―ティカルズ (Kiniksa Pharmaceuticals Ltd.) キニクサ・ファ―マシュ―ティカルズ

 KNSAのチャート


 KNSAの企業情報

symbol KNSA
会社名 Kiniksa Pharmaceuticals Ltd (キニクサ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 キニクサ・ファーマシューティカルズ(Kiniksa Pharmaceuticals Ltd.)は臨床段階のバイオ医薬品会社である。同社は衰弱性疾患に罹患している患者に使用される治療薬の発見、獲得、開発及び商業化に従事する。同社のプログラムには、リロナセプト、マブリリムマブ、KPL-716、KPL-045、KPL-404がある。リロナセプトは、ンターロイキン-1α及びインターロイキン-1βを阻害するタンパク質である。マブリリムマブは、顆粒球マクロファージコロニー刺激因子またはGM-CSFのシグナル伝達に拮抗するモノクローナル抗体である。KPL-716は、それらの共通の受容体サブユニット、オンコスタチンM受容体ベータ、またはOSMRベータを標的とすることによって、インターロイキン31またはIL-31、及びオンコスタチンMまたはOSMのサイトカインのシグナル伝達を同時に阻害するモノクローナル抗体である。KPL-045は、CD30/CD30L相互作用のモノクローナル抗体インヒビターであり、活性化T-メモリー細胞機能に関与するT細胞共刺激レセプターである。KPL-404は、T細胞依存性のB細胞媒介体液性適応免疫の中央制御ノードである。   キニクサ・ファ―マシュ―ティカルズはバミュ―ダ諸島籍のバイオ医薬品企業。有効な治療法が確立されていない衰弱性疾患の治療薬の発見、開発および商品化に焦点を当て事業を行う。主に自己炎症性および自己免疫性疾患の治療薬の臨床試験を手掛ける。主要製品候補には、再発性心膜炎の治療薬Rilonaceptや、巨細胞性動脈炎の治療薬Mavrilimumabなどがある。   Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of assets, ARCALYST, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases.
本社所在地 Clarendon House 2 Church Street Hamilton HM11 BMU
代表者氏名
代表者役職名
電話番号 +1 441-781439-9100
設立年月日 42186
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 47人
url www.kiniksa.com
nasdaq_url https://www.nasdaq.com/symbol/knsa
adr_tso
EBITDA EBITDA(百万ドル) -86.79100
終値(lastsale) 20.46
時価総額(marketcap) 1011842384.52
時価総額 時価総額(百万ドル) 1102.344
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 743.15400
当期純利益 当期純利益(百万ドル) -84.90100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Kiniksa Pharmaceuticals Ltd revenues was not reported. Net loss increased from $16.1M to $36.2M. Higher net loss reflects Research and development - Balancing val increase from $12.4M to $29.3M (expense) General and administrative - Balancing v increase of 81% to $7M (expense) Stock-based Compensation in General and increase from $168K to $1.1M (expense).

 KNSAのテクニカル分析


 KNSAのニュース

   Kiniksa files for $400M mixed shelf offering (NASDAQ:KNSA)  2022/05/06 20:55:57 Seeking Alpha
Kiniksa Pharmaceuticals (KNSA) has filed for a $400M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.
   Kiniksa Pharmaceuticals GAAP EPS of -$0.36 misses by $0.03, revenue of $32.18M (NASDAQ:KNSA)  2022/05/03 12:18:11 Seeking Alpha
Kiniksa Pharmaceuticals press release (KNSA): Q1 GAAP EPS of -$0.36 misses by $0.03.Revenue of $32.18M.
   Earnings Scheduled For May 3, 2022  2022/05/03 08:52:35 Benzinga
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ: KNSA ) is projected to report earnings for its first quarter. • Great Lakes Dredge & Dock (NASDAQ: GLDD ) is likely to report quarterly earnings at $0.16 per share on revenue of $170.53 million. • Enel Chile (NYSE: ENIC ) is expected to report quarterly earnings at $82.88 per share on revenue of $994.35 million. • Paramount Global (NASDAQ: PARAA ) is likely to report quarterly earnings at $0.52 per share on revenue of $7.38 billion. • Triton International (NYSE: TRTN ) is likely to report quarterly earnings at $2.63 per share on revenue of $419.07 million. • Colliers Intl Gr (NASDAQ: CIGI ) is likely to report quarterly earnings at $1.59 per share on revenue of $1.14 billion. • Comstock Mining (AMEX: LODE ) is projected to report quarterly loss at $0.03 per share on revenue of $380.00 thousand. • GEO Group (NYSE: GEO ) is expected to report quarterly earnings at $0.22 per share on revenue of $551.47 million. • Kopin (NASDAQ: KOPN ) is expected to report quarterly loss at $0.
   Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022  2022/05/02 20:01:00 GlobeNewswire
HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. Eastern Time to report its first quarter 2022 financial results and corporate activities.
   Greenberg Traurig Represents Huadong Medicine in Two Licensing Deals Totalling Over $1.6 Billion in Value  2022/03/04 01:10:00 Benzinga
ATLANTA , March 3, 2022 /PRNewswire-PRWeb/ -- Wayne H. Elowe , co-chair of the Life Sciences and Medical Technology Group at global law firm Greenberg Traurig, LLP and co-chair of the firm''s Atlanta Corporate Practice, led the Greenberg Traurig team representing Huadong Medicine Co., Ltd., one of the leading pharmaceutical companies in China with a focus on oncology and Antibody-drug Conjugates research, development, and commercialization, on two large licensing deals, both of which closed in February 2022 . These deals mark the continuation of a longstanding relationship between Huadong Medicine and Greenberg Traurig Shareholders Elowe and Dawn (Dan) Zhang ( Shanghai ) who have represented Huadong in numerous transactions. In the first deal, Elowe advised Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of Huadong Medicine , in a strategic collaboration with Kiniksa Pharmaceuticals, Ltd., a U.S. biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, to develop …
   Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Expected to Announce Quarterly Sales of $16.32 Million  2021/12/15 15:40:46 Transcript Daily
Wall Street analysts predict that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) will report sales of $16.32 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Kiniksa Pharmaceuticals earnings. The highest sales estimate is $16.51 million and the lowest is $16.13 million. The firm is scheduled to issue its next earnings report []
   Morgan Stanley Has $5.35 Million Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)  2021/12/07 09:18:47 Dakota Financial News
Morgan Stanley increased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 115.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 383,934 shares of the companys stock after acquiring an additional 205,803 shares during the quarter. Morgan Stanley owned about 0.56% []
   Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Expected to Post Quarterly Sales of $16.32 Million  2021/11/28 01:30:42 Transcript Daily
Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) will report $16.32 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Kiniksa Pharmaceuticals earnings, with the lowest sales estimate coming in at $16.13 million and the highest estimate coming in at $16.51 million. The firm is []
   Zacks: Analysts Anticipate Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to Announce -$0.45 Earnings Per Share  2021/11/20 08:20:41 Transcript Daily
Equities analysts expect Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to report earnings of ($0.45) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kiniksa Pharmaceuticals earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.41). Kiniksa Pharmaceuticals posted earnings per share of ($0.79) during the same quarter []
   Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock Position Lifted by Geode Capital Management LLC  2021/11/12 09:22:45 Transcript Daily
Geode Capital Management LLC raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 8.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 458,859 shares of the companys stock after acquiring an additional 35,950 shares during the quarter. Geode Capital Management LLC owned []
   Kiniksa issued U.S. patent for treatment of recurrent pericarditis  2021/06/08 20:05:22 Seeking Alpha
   Kiniksa Outlines Next Steps for the Development of Mavrilimumab  2021/06/08 00:00:00 BioSpace
Kiniksa Pharmaceuticals, Ltd.- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications.
   Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis  2021/06/08 00:00:00 BioSpace
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), today announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST® (rilonacept) in the treatment of recurrent pericarditis.
   Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/01 20:01:00 GlobeNewswire
HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 9:40 a.m. Eastern Time.
   Kiniksa Pharmaceuticals Ltd - Class A Shares Approach 52-Week Low - Market Mover  2021/05/21 22:30:00 Kwhen Finance
Kiniksa Pharmaceuticals Ltd - Class A (KNSA) shares closed today at 1.5% above its 52 week low of $13.77, giving the company a market cap of $451M. The stock is currently down 20.9% year-to-date, down 35.3% over the past 12 months, and down 28.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Trading volume this week was 32.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 0.8% lower than its 5-day moving average, 8.0% lower than its 20-day moving average, and 25.8% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -7.0% The company's stock price performance over the past 12 months lags the peer average by 614.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (医薬品 米国株 キニクサ・ファ―マシュ―ティカルズ KNSA Kiniksa Pharmaceuticals Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)